← Back to Search

Plasma Exchange

Plasmapheresis for Frailty

Q: To what demographic are recruitment efforts for this study being directed?

This medical trial requires 100 subjects aged between 50 and 95 with demonstrable signs of age-related fragility. Eligible candidates must not be pregnant, breastfeeding or have advanced terminal illness. They cannot display any rashes or open wounds related to treatment for squamous cell <a href="https://www.withpower.com/clinical-trials/cancer">cancer</a> either. Furthermore, they should score 3&#x3C;x &#x3C;7 on the CSHA Clinical Frailty Scale (see Appendix A; Rockwood, Song, MacKnight et al., 2005; Golpanian DiFede Pujol et al., 2016). Finally, they must also be able to remain motionless in an environment conducive to <a href="https://www.withpower.com/clinical-trials/sleep">sleep</a> without difficulty.

Q: Is eligibility for this medical experiment restricted to people above a certain age?

This clinical trial requires applicants between the ages of 50 and 95 to qualify. There are a total of 6 studies catering to minors, while individuals aged 65 or older have access to 144 seperate trials.

Q: Is this experiment currently accepting participants?

Contrary to expectations, clinicaltrials.gov reveals the study has ceased recruiting patients since April 11th 2022 - though there are still 146 other medical studies that require volunteers. The trial was initially posted on March 19 2021.

Phase < 1

Waitlist Available

Led By Sheldon Jordan, M.D.

Research Sponsored by Neurological Associates of West Los Angeles

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age eligibility requirements fall in a range from 50 to 95 years of age

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up change in scale score after completion of study (6 months)

Awards & highlights

Study Summary

This trial will test a new treatment for age-related frailty, which is characterized by reduced physical, cognitive, and immunological functioning. The treatment is called albumin-infused plasmapheresis, and it will be given using the Fresenius Kabi 'Amicus' apheresis machine. The trial will also evaluate the safety and tolerability of repeated plasmapheresis treatment.

Who is the study for?

This trial is for people aged 50-95 showing signs of age-related frailty, which includes weakened physical, cognitive, and immune functions. Participants must score between 3 and 7 on the CSHA Clinical Frailty Scale. It's not open to pregnant or breastfeeding women, those with terminal illnesses, syphilis, inability to lay still for long periods, or with rashes/open wounds.Check my eligibility

What is being tested?

The study tests how effective plasmapheresis (filtering blood plasma) is in treating age-related frailty using a machine called 'Amicus'. The process involves replacing a patient's plasma with albumin solution to see if it improves their condition.See study design

What are the potential side effects?

Potential side effects may include discomfort at the injection site from where blood is drawn and returned during treatment. There might also be risks associated with fluid shifts due to plasma exchange such as dizziness or fatigue.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 50 and 95 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ change in scale score after completion of study (6 months)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~change in scale score after completion of study (6 months)

This trial's timeline: 3 weeks for screening, Varies for treatment, and change in scale score after completion of study (6 months) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in Canadian Study of Health and Aging (CSHA) Clinical Frailty Scale

Trial Design

1Treatment groups

Experimental Treatment

Group I: Experimental Group (Plasmapheresis for Age-Related Frailty)Experimental Treatment1 Intervention

Participants will receive plasmapheresis once a month for six months. All participants will be in this arm.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Neurological Associates of West Los AngelesLead Sponsor

25 Previous Clinical Trials

3,860 Total Patients Enrolled

Sheldon Jordan, M.D.Principal InvestigatorNeurological Associates The Interventional Group

4 Previous Clinical Trials

815 Total Patients Enrolled

Media Library

Therapeutic Plasma Exchange (TPE) (Plasma Exchange) Clinical Trial Eligibility Overview. Trial Name: NCT05054894 — Phase < 1

Age-Related Frailty Research Study Groups: Experimental Group (Plasmapheresis for Age-Related Frailty)

Age-Related Frailty Clinical Trial 2023: Therapeutic Plasma Exchange (TPE) Highlights & Side Effects. Trial Name: NCT05054894 — Phase < 1

Therapeutic Plasma Exchange (TPE) (Plasma Exchange) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05054894 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what demographic are recruitment efforts for this study being directed?

"This medical trial requires 100 subjects aged between 50 and 95 with demonstrable signs of age-related fragility. Eligible candidates must not be pregnant, breastfeeding or have advanced terminal illness. They cannot display any rashes or open wounds related to treatment for squamous cell cancer either. Furthermore, they should score 3<x <7 on the CSHA Clinical Frailty Scale (see Appendix A; Rockwood, Song, MacKnight et al., 2005; Golpanian DiFede Pujol et al., 2016). Finally, they must also be able to remain motionless in an environment conducive to sleep without difficulty."

Answered by AI

Is eligibility for this medical experiment restricted to people above a certain age?

"This clinical trial requires applicants between the ages of 50 and 95 to qualify. There are a total of 6 studies catering to minors, while individuals aged 65 or older have access to 144 seperate trials."

Answered by AI

Is this experiment currently accepting participants?

"Contrary to expectations, clinicaltrials.gov reveals the study has ceased recruiting patients since April 11th 2022 - though there are still 146 other medical studies that require volunteers. The trial was initially posted on March 19 2021."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Plasmapheresis for Treatment of Age-Related Frailty

2021. "Plasmapheresis for Treatment of Age-Related Frailty". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05054894.